Prova EducationCME: Management of CRS and ICANS with CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma

Global Learning Collaborative (GLC) designates this 15-minute enduring activity for a maximum of .25 AMA PRA Category 1 Credits™ and .25 nursing contact hours.

Dive into the intriguing realm of CAR T-cell therapy management, specifically pertaining to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Discover the latest clinical data and strategies to optimize patient outcomes.

Key Points:

• CAR T-cell therapy is a potentially transformative treatment for relapsed/refractory multiple myeloma.
• Current consensus grading systems exist for CRS and ICANS associated with CAR T-cell therapy.
• Understanding the signs and symptoms of CRS and ICANS is crucial for effective patient management.

Additional Points:

• Interdisciplinary team strategies are pivotal for successful management of CRS and ICANS in this patient population.
• This CME activity targets a wide array of healthcare professionals, including hematologists, oncologists, nurse practitioners, physician assistants, and nurses.

Conclusion:

• This educational activity serves as an essential guide for healthcare professionals seeking to deepen their understanding and effective management of CRS and ICANS in patients receiving CAR T-cell therapy.

Nursing Latest Posts

• Court Allows DNP’s Defamation Case Against Physician to ProceedNovember 11, 2024
• NPs and PAs Salaries and Burnout: A Step in the Right Direction, But More Action Is NeededOctober 24, 2024
• How to Properly Manage Missed Doses of Long-Acting Injectable MedicationsAugust 27, 2024
• Telephone Triage Nursing: When Patients CallMay 28, 2024

Did You Know?
According to research, CAR T-cell therapy has demonstrated impressive response rates of more than 80% in some studies with multiple myeloma patients who have exhausted other treatment options.